DRKS00016666
Completed
Not Applicable
An observational multicentre study to confirm the safety and performance of the BeGraft Peripheral Stent Graft System (BGP) in renal arteries - BGP-2, BGP in renal arteries
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- I70.1
- Sponsor
- Bentley InnoMed GmbH
- Enrollment
- 32
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with an indication for intraluminal chronic placement of a BeGraft Peripheral Stent Graft System in renal arteries or patients who have already received a BeGraft Peripheral Stent Graft System can be included if:
- •The treatment is for restoring and improving the patency or treating aneurysms, acute perforations, acute ruptures or fistulas
- •They have a signed data privacy consent
- •Criteria for renal interventions is given according to relevant guidelines
Exclusion Criteria
- •Patients with any contraindication according to the IFU (instructions for use)
- •Intolerance to antiplatelet therapy
- •Lytic agent administered in the past 30 days
- •History of bleeding diathesis
- •Coagulopathy
- •Gastrointestinal hemorrhage within the past 6 months
- •Life expectancy less than 1 year
- •Dialytic patients
- •BGP is used in combination with an EVAR/S device for the treatment of an aorta aneurysm
- •BGP as a bridging stent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Multicenter observational study for determination of prognostic factors in metastatic breast cancersocally advanced and metastatic breast cancerJPRN-UMIN000038356Hyogo College of Medicine600
Recruiting
Not Applicable
multicenter observational study investigating the relationship between worsening of forward flexion of trunk and deterioration of perceiving the vertical position in Parkinson disease patientsParkinson diseaseJPRN-UMIN000037654St.Marianna University School of Medicine150
Not yet recruiting
Not Applicable
A multicenter observational study to evaluate the efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with unresectable neuroendocrine tumors (NEN).JPRN-UMIN000054127ational cancer center200
Recruiting
Not Applicable
A multicenter observational study to evaluate the association between mineralocorticoid receptor antagonist and urine albumin-creatinine ratio at 6 months in heart failure patients with hypertensioHypertension, heart failure, chronic kidney diseaseJPRN-UMIN000049598Tohoku University Graduate School of Medicine200
Completed
Not Applicable
A multicenter study on the safety of tapentadolCancer painJPRN-UMIN000044282Yokohama city university600